ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1291

Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus

Eun Song Kang1, Ji Seon Oh2, Soo Min Ahn1, Yong Gil Kim1, Chang-Keun Lee1, Bin Yoo3 and Seokchan Hong3, 1Asan Medical Center, Seoul, Republic of Korea, 2Asan Medical Center, Ulsan, Republic of Korea, 3Asan Medical Center, Seoul, South Korea

Meeting: ACR Convergence 2021

Keywords: American College of Rheumatology Criteria, Lupus nephritis, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of bleeding-related complications is not low in such patients, data on the risk of percutaneous kidney biopsy in SLE patients are limited. Thus, we investigated the rate of bleeding-related complications and examined the risk factors for complications of kidney biopsy in patients with SLE.

Methods: We retrospectively reviewed the medical records of SLE patients who underwent ultrasound-guided percutaneous kidney biopsy between 2002 and 2020 at a tertiary referral center. Major complications included bleeding events that required interventions (e.g., blood transfusion, angiographic embolization, surgery) after biopsy. Minor complications included hematoma, oozing at the biopsy site, and passing hematuria without a need for intervention. Statistical analysis with a multivariate logistic regression model was performed to identify the risk factors associated with complications.

Results: In a total of 165 SLE patients, the rate of overall bleeding-related complication after kidney biopsy was 25% (major: 8%, minor: 17%). In terms of the details of major complications, 86% (12/14) of patients needed a blood transfusion alone without embolization or surgery, and the remaining two patients needed embolization for bleeding control. Patients with any kind of complication had a significantly lower platelet level than did those without complications (p< 0.001). Univariate analysis showed that the levels of hemoglobin (OR 0.81; 95% CI, 0.66–0.99), platelet (OR 0.99; 95% CI, 0.99–1.00), aPTT (OR 1.05; 95% CI, 1.00–1.11), and proteinuria (OR 1.00; 95% CI, 1.00–1.00) were significantly associated with the risk of complications. Multivariate analysis revealed that low platelet count (OR 0.99; 95% CI, 0.98–0.99) was significantly associated with the risk of bleeding-related complications after kidney biopsy.

Conclusion: Percutaneous kidney biopsy was accompanied by the risk of bleeding-related complications, although the majority of events did not require vascular intervention for bleeding control. Low levels of platelet counts had a significantly increased risk of complications after kidney biopsy in patients with SLE.

BMI: body mass index; sBP: systolic blood pressure; PT INR : prothrombin time international normalized ratio; aPTT: activated partial thromboplastin time; eGFR: estimated glomerular filtration rate; C3/C4: complement 3/4ESR: erythrocyte sedimentation rate; ACA: anticentromere antibody; B2-GPI: Beta_2-glycoprotein I antibody ACEi/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker ISN/RPS: International Society of Nephrology and Renal Pathology Society

sBP: systolic blood pressure; PT INR : prothrombin time international normalized ratio; aPTT: activated partial thromboplastin time; eGFR: estimated glomerular filtration rate; C3: complement 3 ESR: erythrocyte sedimentation rate; ACA: anticentromere antibody; B2-GPI: Beta_2-glycoprotein I antibody


Disclosures: E. Kang, None; J. Oh, None; S. Ahn, None; Y. Kim, None; C. Lee, None; B. Yoo, None; S. Hong, None.

To cite this abstract in AMA style:

Kang E, Oh J, Ahn S, Kim Y, Lee C, Yoo B, Hong S. Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-bleeding-related-complications-after-kidney-biopsy-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-bleeding-related-complications-after-kidney-biopsy-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology